Valued at a market cap of $11.6 billion, Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. The Waltham, Massachusetts-based company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. It is expected to announce its fiscal Q2 earnings for 2025 before the market opens on Monday, Jul. 28.
Ahead of this event, analysts expect this healthcare company to report a profit of $1.14 per share, down 6.6% from $1.22 per share in the year-ago quarter. The company has topped Wall Street’s earnings estimates in each of the last four quarters. In Q1, Revvity’s EPS of $1.01 outpaced the forecasted figure by 5.2%.
For fiscal 2025, analysts expect RVTY to report a profit of $4.82 per share, down 1.6% from $4.90 per share in fiscal 2024. Nonetheless, its EPS is expected to rebound in fiscal 2026, growing by 14.3% year-over-year to $5.51.
Shares of RVTY have declined 10.1% over the past 52 weeks, lagging behind both the S&P 500 Index’s ($SPX) 11.6% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 8.9% loss over the same time frame.
On Apr. 28, shares of Revvity closed up marginally after its Q1 earnings release. Due to growth in revenue across both of its reportable segments, the company’s overall revenue improved 2.3% year-over-year to $664.8 million. Moreover, its adjusted EPS from continuing operations advanced 3.1% from the year-ago quarter to $1.01 and topped the consensus expectations by 5.2%. Lower adjusted operating income from the diagnostics segment was more than offset by a robust rise in the life sciences segment’s profits.
Looking ahead, Revvity raised its fiscal 2025 revenue guidance to a range of $2.8 billion to $2.9 billion and reaffirmed its adjusted EPS outlook of $4.90 to $5, which may have further bolstered investor confidence.
Wall Street analysts are moderately optimistic about Revvity’s stock, with a “Moderate Buy” rating overall. Among 17 analysts covering the stock, 10 recommend “Strong Buy,” one indicates a “Moderate Buy,” and six advise “Hold.” The mean price target for RVTY is $118.69, indicating a 20.5% potential upside from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
